TB Research

IDENTIFYING LEAD COMPOUNDS FOR POTENTIAL ANTI-TUBERCULOSIS DRUGS BY IN SILICO MYCOBACTERIUM TUBERCULOSIS SHIKIMATE KINASE INHIBITORS SELECTION OF CHEMICAL LIBRARY

Nuki Bambang Nugroho, BELLA ETIKA, Sri Teguh Rahayu, Adjar Wibowo, Eka Siska

International Journal of Applied Pharmaceutics · 2025-03

Abstract

Objective: The present study aimed to identify Shikimate Kinase (SK) inhibitors as antitubercular agents from a chemical library by the utilization of molecular docking simulation, pharmacophore evaluation, and Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) prediction approaches. Methods: A molecular docking study by Molecular Operating Environment (MOE) was used to screen 400,000 compounds from the Mcule ULTIMATE Express 1 chemical library. This docking study used a rigid docking technique to simulate the interaction between receptors and compounds. The screened compounds were then validated by pharmacophore and ADMET analyses to show the presence of positive characteristics. Results: The result of molecular docking simulation identified N-[2-(diethylamino)ethyl]-2-(pyrrolidin-1-yl)acetamide as the most promising candidate for targeting Mycobacterium tuberculosis Shikimate Kinase (MtSK), due to its binding energy score (-11.3412 kcal/mol) and suitability of interacting residues (Asp34 and Gly80). Moreover, this compound also shared similar pharmacophores with shikimate, and it had positive drug-like and ADMET properties. Conclusion: This work identified one candidate for SK inhibitor from a pool of five drug-like hit compounds. These inhibitors show promise as prospective candidates for the development of a new anti-tuberculosis therapy and warrant additional experimental investigation.

MeSH terms

  • In silico
  • Mycobacterium tuberculosis
  • Tuberculosis
  • Lead compound
  • Selection (genetic algorithm)
  • Shikimate pathway
  • Pharmacology
  • Chemistry
  • Biology
  • Virology
  • Microbiology